LY 4006896
Alternative Names: LY-4006896Latest Information Update: 10 Mar 2025
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 18 Feb 2025 Phase-I clinical trials in Parkinson's disease (In volunteers) in USA (IV) (NCT06809400)
- 05 Feb 2025 Eli Lilly and Company plans phase-I trial for Parkinson's disease (In Adults, In the elderly) in USA (IV) in February 2025 (NCT06809400)
- 05 Feb 2025 Preclinical trials in Parkinson's disease in USA (IV) (NCT06809400)